Phase 3 Recruiting NIH
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in Arizona: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Arizona: - Kingman Regional Medical Center — Kingman, Arizona
- Banner Children's at Desert — Mesa, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in Arizona: - Banner Children's at Desert — Mesa, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in Arizona: - Phoenix Childrens Hospital — Phoenix, Arizona
Phase 3 Recruiting Network
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in Arizona: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Phase 3 Recruiting Industry
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Sponsor: Polaris Group
NCT ID: NCT05712694
Sites in Arizona: - Mayo Clinic Arizona — Phoenix, Arizona
Phase 3 Recruiting Industry
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Indepe…
Sponsor: PharmaMar
NCT ID: NCT06088290
Sites in Arizona: - Mayo Clinic Hospital - Phoenix — Phoenix, Arizona
Phase 3 Recruiting Industry
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride…
Sponsor: Advenchen Laboratories, LLC
NCT ID: NCT03016819
Sites in Arizona: - Mayo Clinic Arizona — Phoenix, Arizona
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Arizona: - Mayo Clinic - Scottsdale — Scottsdale, Arizona
- University of Arizona — Tucson, Arizona
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people wi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05634369
Sites in Arizona: - Phoenix Children's Hospital — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \…
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06541262
Sites in Arizona: - Phoenix Children's Hospital — Phoenix, Arizona
Phase 2 Recruiting Academic/Other
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activat…
Sponsor: Carl Allen
NCT ID: NCT04079179
Sites in Arizona: - Phoenix Children's Hospital — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Sponsor: ImmVira Pharma Co. Ltd
NCT ID: NCT04370587
Sites in Arizona: - Banner MD Anderson Cancer Center — Gilbert, Arizona
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…
Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Industry
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous…
Sponsor: Haihe Biopharma Co., Ltd.
NCT ID: NCT04390737
Sites in Arizona: - Mayo Clinic — Phoenix, Arizona
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Arizona: - Mayo Clinic - Phoenix — Phoenix, Arizona
Phase 1 Recruiting Industry
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in Arizona: - Mayo Clinic — Phoenix, Arizona
Phase 1 Recruiting Industry
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT03715933
Sites in Arizona: - HonorHealth Research Institute — Scottsdale, Arizona
Phase 1 Recruiting Academic/Other
This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that a…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT07194044
Sites in Arizona: - Phoenix Children's Hospital — Phoenix, Arizona
Phase 1 Recruiting Industry
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-…
Sponsor: Y-mAbs Therapeutics
NCT ID: NCT05130255
Sites in Arizona: - HonorHealth — Scottsdale, Arizona
Phase 1 Recruiting Industry
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid mal…
Sponsor: BioEclipse Therapeutics
NCT ID: NCT04282044
Sites in Arizona: - HonorHealth Research Institute — Scottsdale, Arizona
Phase 1 Recruiting Academic/Other
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed fo…
Sponsor: City of Hope Medical Center
NCT ID: NCT05227326
Sites in Arizona: - Honor Health Research and Innovation Institute — Scottsdale, Arizona
EARLY Phase 1 Recruiting Academic/Other
The goal of this clinical trial is to to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy. The main questions it aims to answer are…
Sponsor: Children's Hospital Medical Center, Cincinnati
NCT ID: NCT07048249
Sites in Arizona: - Phoenix Children's — Phoenix, Arizona
Phase 1 Recruiting Academic/Other
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cance…
Sponsor: Mayo Clinic
NCT ID: NCT06712810
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Arizona: - Kingman Regional Medical Center — Kingman, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona